WILMINGTON, N.C., Feb. 22 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced that its board of directors declared a cash dividend for the first quarter of 2008 under its annual cash dividend policy. The quarterly cash dividend will equal $0.10 per share. The record date for the first quarter dividend is March 14, 2008, and the payment date is March 28, 2008. The annual cash dividend policy and the payment of future quarterly cash dividends under that policy are subject to the continuing determination by the board of directors that the policy remains in the best interests of the company's shareholders and in compliance with applicable laws and agreements.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,200 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations
and assumptions, including expectations and assumptions about the payment
of future cash dividends under the annual dividend policy, contained in
this news release are forward-looking statements that involve a number of
risks and uncertainties. Although PPD attempts to be accurate in making
these forward- looking statements, it is possible that future circumstances
might differ from the assumptions on which such statements are based. In
addition, other important factors which could cause results to differ
materially include the following: risks that we may not continue our
dividend policy; economic conditions and outsourcing trends in the
pharmaceutical, biotechnology and medical device industries and
government-sponsored research sector; continued success in sales growth;
loss of large contracts; competition within the outsourcing industry; the
ability to attract and retain key personnel; dependence on collaborative
relationships; rapid technological advances that make our products and
services less competitive; and the other risk factors set forth from time
to time in the SEC filings for PPD, copies of which are available free of
charge upon request from the PPD investor relations department.
+910 558 7915
+910 558 7585
|SOURCE PPD, Inc.|
Copyright©2008 PR Newswire.
All rights reserved